NR3C2 and heart failure: As of 2021, the standard of care for heart failure with reduced ejection fraction (HFrEF) involves quadruple medical therapy combining angiotensin receptor-neprilysin inhibitors (ARNI), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium/glucose cotransporter 2 inhibitors (SGLT2 inhibitors) [2].